Gilead Sciences Reports Positive Long-Term Data for Livdelzi and Receives EMA Support for Trodelvy
Gilead Sciences (NASDAQ: GILD) reported positive long-term efficacy data from its Phase 3 ASSURE study of Livdelzi in treating primary biliary cholangitis. Additionally, the European Medicines Agency's CHMP issued a favorable opinion recommending marketing authorization for Trodelvy as first-line monotherapy for triple-negative breast cancer.
Tickers: $GILD
Topics: Gilead Sciences Livdelzi primary biliary cholangitis triple-negative breast cancer Trodelvy